The clinician who understands the physicochemical principles of local anesthetic pharmacology, including pKa, lipid solubility, protein binding, and state-dependent channel block, is equipped to understand why individual agents behave differently in practice. This module applies that foundation to the specific pharmacologic profiles of the clinically available local anesthetics, organized by chemical class. It also addresses the rational use of adjuvants that modify onset, duration, and quality of block without contributing to the intrinsic anesthetic effect. The distinction between ester and amide agents extends well beyond a chemical curiosity: it determines metabolic pathway, allergy profile, and the clinical consequences of impaired elimination. Within each chemical class, understanding the structural basis of pharmacokinetic differences enables rational agent selection for a given clinical scenario rather than reliance on habit or institutional custom.¹

Cocaine is the only naturally occurring local anesthetic and the prototypical ester agent, derived from the leaves of Erythroxylon coca. Its pharmacologic profile is unique among local anesthetics in two important respects: it is a potent inhibitor of presynaptic monoamine reuptake transporters (dopamine, norepinephrine, serotonin), producing intense sympathomimetic effects and vasoconstriction, and it is the only local anesthetic with intrinsic vasoconstrictive properties sufficient to make it genuinely useful as a single-agent topical preparation for mucosal surfaces.³ These properties made it the dominant local anesthetic from its introduction in the 1880s through the development of synthetic alternatives in the early twentieth century.

Clinically, cocaine retains a narrow but well-defined role in otolaryngologic and rhinologic procedures, particularly nasal and nasopharyngeal surgery, where its combination of surface anesthesia and vasoconstriction simultaneously provides analgesia and a bloodless operative field.³ It is applied topically as a 4–10% solution to nasal mucosa, typically on pledgets or by spray; systemic absorption through nasal mucosa is significant and can produce tachycardia, hypertension, coronary artery spasm, and cardiac dysrhythmias, particularly in patients with underlying cardiovascular disease or those receiving adrenergic agents. The maximum topical dose is generally cited at 1.5–3 mg/kg, with a practical ceiling of approximately 200 mg in a healthy adult; doses above this threshold carry meaningful risk of systemic toxicity.³ Cocaine is a Schedule II controlled substance; its use requires careful documentation, and diversion is a recognized clinical concern in procedural settings where it is stocked. True allergy to cocaine as an ester agent is possible but rare; most adverse reactions in clinical settings are sympathomimetic rather than immunologic.

Procaine (Novocain) was the first synthetic local anesthetic, introduced in 1905 by Alfred Einhorn specifically to provide a less toxic and less addictive alternative to cocaine. It is an ester with a pKa of 8.9, poor lipid solubility, low potency, and minimal protein binding (~6%), resulting in impaired onset (a large fraction remains in the charged form at physiologic pH), short duration of action (30–60 minutes without epinephrine), and a requirement for relatively high concentrations to achieve clinical effect.² Procaine is rapidly hydrolyzed by plasma cholinesterase to para-aminobenzoic acid (PABA) and diethylaminoethanol; PABA is the metabolite responsible for the allergic reactions historically associated with ester local anesthetics, and is also a competitive antagonist of sulfonamide antibiotics, a pharmacologic interaction of historical but diminishing clinical relevance. Procaine's clinical use has declined substantially with the advent of superior agents. It retains some use in spinal anesthesia for very short procedures where its brief duration is advantageous, and occasionally in patients with documented amide allergy where an alternative class is required. Its historical significance is considerable; most of the early clinical and pharmacologic understanding of local anesthesia was developed using procaine as the reference compound.⁴

Chloroprocaine (Nesacaine) is a chlorinated derivative of procaine with a pKa of 8.7, low lipid solubility, and minimal protein binding (~6%). Despite the high pKa that would otherwise predict slow onset, chloroprocaine is used clinically at high concentrations (2–3%) that overcome the ionization disadvantage by mass action, producing rapid onset (typically 6–12 minutes for epidural administration) that is faster than lidocaine at equivalent volume.⁵ Its defining pharmacokinetic feature is an exceptionally short plasma half-life of less than 60 seconds, attributable to rapid hydrolysis by plasma cholinesterase. This makes it the safest local anesthetic from a systemic toxicity standpoint in terms of plasma accumulation; accidental intravascular injection of chloroprocaine, while still capable of producing transient central nervous system (CNS) effects, is far less likely to produce sustained cardiovascular toxicity than an equivalent volume of bupivacaine or lidocaine.⁵

Chloroprocaine has an important and well-established role in obstetric epidural anesthesia, particularly for urgent conversion of labor epidurals to surgical anesthesia for cesarean delivery. Its rapid onset and exceptional safety margin in the event of intravascular injection make it the preferred agent in many obstetric units for this indication.⁵ A historical concern involved epidural administration of large volumes of the earlier formulation, which contained the preservative sodium bisulfite; high concentrations in the epidural or intrathecal space were associated with adhesive arachnoiditis and prolonged neurologic deficits. This complication was attributed to the bisulfite preservative rather than chloroprocaine itself, and the currently available preservative-free formulation is not associated with neurotoxicity at clinical doses. A separate and clinically important interaction: chloroprocaine applied to the epidural space may significantly impair the subsequent efficacy of epidurally administered opioids and bupivacaine, likely through pH alteration and competitive displacement; the mechanism is not fully elucidated, but the clinical consequence (termed "chloroprocaine tachyphylaxis") is well recognized, and clinicians should be aware that switching from chloroprocaine to another epidural agent immediately after large-dose chloroprocaine administration may produce inadequate subsequent analgesia.⁵

Tetracaine (Pontocaine, amethocaine) is a long-acting ester with high lipid solubility, high protein binding, and high potency, properties that more closely resemble the long-acting amides bupivacaine and ropivacaine than the other esters.¹ Its primary clinical application is spinal anesthesia, where it provides dense sensorimotor block of 2–3 hours duration (4–6 hours with epinephrine), and topical ophthalmic anesthesia. Tetracaine is not used for peripheral nerve blocks or epidural anesthesia due to its slower hydrolysis relative to other esters (a consequence of its structural modifications) and the narrow therapeutic window associated with its high potency and lipid solubility.⁴ Topical tetracaine gel (Ametop, 4%) has established efficacy for dermal analgesia prior to venipuncture, particularly in pediatric patients, with onset in 30–45 minutes and a somewhat faster and more consistent onset than Eutectic Mixture of Local Anesthetics (EMLA) cream.¹

Benzocaine is unique among clinically used local anesthetics in that it exists almost entirely in the uncharged free base form under physiologic conditions; it lacks a hydrophilic amine terminus capable of protonation in the relevant pH range, making it essentially a permanently uncharged molecule with a pKa below 3.5.¹ This means it cannot be formulated as a water-soluble injectable salt and is used exclusively for topical application. Benzocaine 20% sprays are widely used for topical mucosal anesthesia prior to upper endoscopy, nasotracheal intubation, and bronchoscopy.

Its primary toxicologic concern is methemoglobinemia: benzocaine oxidizes the ferrous iron (Fe²⁺) of hemoglobin to the ferric state (Fe³⁺), producing methemoglobin, which cannot carry oxygen. Clinically significant methemoglobinemia (methemoglobin >20–30%) causes cyanosis, dyspnea, anxiety, and cardiovascular collapse and death at levels above 50–70%.⁶ The risk is highest in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, infants whose fetal hemoglobin is more susceptible to oxidation and whose methemoglobin reductase system is incompletely developed, and patients with pre-existing hypoxia or anemia. Methemoglobinemia is treated with methylene blue 1–2 mg/kg IV, which serves as an electron donor to the nicotinamide adenine dinucleotide phosphate (NADPH) methemoglobin reductase system, rapidly reducing methemoglobin back to functional hemoglobin.⁶ This complication, while rare with careful benzocaine use, is unpredictable in individual patients and has led some institutions to restrict or eliminate benzocaine sprays in favor of viscous lidocaine or other topical preparations.

The clinical utility of local anesthetics is frequently extended by the co-administration of adjuvants: agents that modify the onset, duration, quality, or spread of neural blockade without themselves possessing primary local anesthetic activity. A clear understanding of the pharmacologic basis, clinical evidence, and safety profile of each adjuvant is essential for rational use, as their administration into epidural, intrathecal, or perineural spaces is not without risk.

Epinephrine is the most widely used local anesthetic adjuvant and the most pharmacologically well-characterized. Its primary mechanism in the context of regional anesthesia is α₁-adrenergic receptor–mediated vasoconstriction at the injection site, which reduces local blood flow and slows systemic absorption of the local anesthetic, prolonging its residence at the nerve and extending block duration.¹ A secondary mechanism, relevant particularly in the neuraxial context, is direct antinociceptive activity at spinal α₂-adrenergic receptors, which contributes independently to analgesia through a mechanism shared with clonidine and dexmedetomidine.¹² The magnitude of epinephrine's effect on block duration varies substantially by agent. For lidocaine, epinephrine extends peripheral nerve block duration by approximately 50–100%; for bupivacaine and ropivacaine, the proportional extension is smaller (approximately 15–30%) because these agents already have high lipid solubility and protein binding that sustains neural binding independently of vascular absorption rate.¹

Epinephrine is typically added at concentrations of 1:200,000 (5 μg/mL) for peripheral nerve blocks and epidural anesthesia; higher concentrations (1:100,000) are used for dental infiltration. The standard test dose before epidural dosing incorporates epinephrine 15 μg: intravascular injection of this dose produces a characteristic tachycardia of ≥20 bpm within 45–60 seconds, serving as a warning sign of intravascular needle or catheter placement before the full local anesthetic dose is administered.¹²

Contraindications to epinephrine-containing solutions are anatomically defined: end-arterial sites (digits, penis, pinna, nose) where vasoconstriction eliminates collateral flow and risks ischemic necrosis; intravenous regional anesthesia (Bier block) where epinephrine is unnecessary and potentially dangerous upon tourniquet release; and patients with severe uncontrolled hypertension, unstable coronary artery disease, or those receiving monoamine oxidase inhibitors, where exaggerated systemic adrenergic responses may occur.¹²

Alkalinization of local anesthetic solutions with sodium bicarbonate shifts the ionization equilibrium toward the free base form, theoretically accelerating onset by increasing the membrane-permeable fraction at the site of injection. Bicarbonate is typically added as 1 mEq per 10 mL of lidocaine solution, raising pH from approximately 6.5 to 7.2, or 0.1 mEq per 10 mL of bupivacaine, since higher doses precipitate bupivacaine at alkaline pH. The clinical evidence for bicarbonate-induced onset acceleration is strongest for epidural lidocaine, where multiple randomized trials demonstrate a reduction in epidural onset time of 2–5 minutes, and weaker or inconsistent for peripheral nerve blocks, where the physiologic buffering capacity of tissue may rapidly overcome the exogenous alkalinization.¹³ Bicarbonate alkalinization does not meaningfully alter block quality or duration, and its benefit in any individual clinical scenario must be weighed against the practical inconvenience of preparation and the risk of bupivacaine precipitation if incorrect concentrations are used.

Perineural or systemic dexamethasone has emerged as one of the most effective and evidence-supported adjuvants for prolonging peripheral nerve block duration. Systemic dexamethasone (8 mg IV) and perineural dexamethasone (4–8 mg) both extend the duration of intermediate-acting and long-acting peripheral nerve blocks by approximately 6–8 hours, with some studies demonstrating total block durations exceeding 24 hours when dexamethasone is combined with long-acting local anesthetics.¹⁴ The mechanisms are not fully characterized but likely include local anti-inflammatory effects reducing inflammatory sensitization of nociceptors, direct suppression of nociceptive C-fiber discharge, and systemic anti-inflammatory and analgesic effects when absorbed or when given systemically. Whether perineural administration provides additional benefit beyond the systemic effect remains debated; meta-analyses suggest that the IV route and the perineural route are approximately equivalent in their duration-extending effect, which has practical implications; it may be preferable to administer dexamethasone IV rather than perineurally to avoid uncertain long-term local effects of corticosteroids on neural tissue.¹⁴ The clinical benefit of dexamethasone is most pronounced in the context of ambulatory surgery, where extending nerve block analgesia into the first postoperative night dramatically reduces opioid consumption and improves patient satisfaction and recovery.

Clonidine, an α₂-adrenergic receptor agonist, prolongs both sensory and motor components of peripheral nerve blocks by approximately 2–4 hours when added perineurally.¹² Its mechanism at the peripheral nerve involves hyperpolarization of nociceptor membranes through Gi-coupled reduction in cAMP, which raises the threshold for action potential generation, with possible contributions from local vasoconstrictive effects that slow local anesthetic absorption. At the neuraxial level, clonidine provides analgesia through direct α₂ receptor activation in the dorsal horn of the spinal cord, suppressing substance P release and reducing ascending nociceptive transmission.¹² The primary clinical limitation of perineural clonidine is systemic absorption producing dose-dependent sedation and hypotension, which limits the practical perineural dose to approximately 0.5–1 μg/kg; at doses above this range, systemic effects may outweigh the peripheral benefit.

Dexmedetomidine, the highly selective α₂-adrenergic agonist used for procedural sedation and intensive care unit (ICU) analgosedation, has gained interest as a perineural adjuvant based on its greater α₂ receptor selectivity compared to clonidine (α₂:α₁ ratio of approximately 1600:1 versus 220:1 for clonidine). Perineural dexmedetomidine at doses of 50–100 μg has demonstrated block duration extension of 4–8 hours in multiple randomized trials, with effects on both sensory and motor block duration.¹² However, systemic absorption of perineural dexmedetomidine is significant and produces sedation and bradycardia at these doses, raising questions about whether the analgesic benefit is peripherally or centrally mediated, analogous to the ongoing debate surrounding the route of dexamethasone administration. Dexmedetomidine is not currently FDA-approved as a perineural adjuvant, and its use in this context remains off-label; given the sedation and hemodynamic effects, careful patient monitoring is required.

Ester local anesthetics are hydrolyzed by plasma pseudocholinesterase (butyrylcholinesterase), the same enzyme responsible for succinylcholine metabolism. In patients with pseudocholinesterase deficiency, whether inherited (dibucaine-resistant variants, including homozygous atypical, silent, or fluoride-resistant genotypes) or acquired (severe hepatic disease, pregnancy, malnutrition, burns, or certain drug exposures including echothiophate and organophosphates), the hydrolysis of ester local anesthetics is substantially slowed.² The clinical consequence is prolonged plasma half-life and elevated systemic exposure for any ester agent administered. For chloroprocaine, whose exceptional safety profile depends entirely on its near-instantaneous hydrolysis: pseudocholinesterase deficiency transforms a drug with a plasma half-life of under 60 seconds into one with a half-life of minutes to tens of minutes, eliminating the kinetic safety advantage that makes it the preferred agent for urgent obstetric epidural conversion. For procaine and tetracaine, which have longer baseline half-lives, deficiency further extends duration and increases the risk of systemic accumulation with repeated dosing.

The dibucaine number is the standard clinical test for pseudocholinesterase activity: it measures the percentage inhibition of pseudocholinesterase by dibucaine under defined conditions. Normal enzyme produces a dibucaine number of 70–85; the homozygous atypical variant produces a number of 20–30, and the heterozygous variant produces an intermediate number of 40–60. In patients with a known history of prolonged succinylcholine effect or a family history of anesthetic complications, the dibucaine number should prompt careful consideration before ester agents are used in doses that depend on rapid systemic clearance for their safety profile. In patients with acquired pseudocholinesterase deficiency from hepatic disease or pregnancy, the degree of impairment is generally modest and rarely produces clinically significant prolongation of ester hydrolysis at typical clinical doses, but awareness of the principle allows appropriate caution when large-volume ester techniques are planned.²

Amide local anesthetics are metabolized primarily by hepatic CYP3A4 (cytochrome P450 3A4) and CYP1A2 (cytochrome P450 1A2). Drugs that inhibit CYP3A4, including azole antifungals (fluconazole, itraconazole, ketoconazole), macrolide antibiotics (erythromycin, clarithromycin), HIV protease inhibitors, and certain calcium channel blockers (diltiazem, verapamil), reduce the hepatic clearance of amide local anesthetics, elevating plasma concentrations for a given dose and prolonging half-life. The clinical relevance of this interaction is greatest for patients receiving continuous infusions or repeated bolus dosing of long-acting amides, particularly bupivacaine and ropivacaine, where steady-state plasma concentrations are already close to the toxic threshold.² CYP1A2 inhibitors, including fluvoxamine and ciprofloxacin, reduce clearance of ropivacaine specifically, since ropivacaine is more dependent on CYP1A2 than bupivacaine. Smoking induces CYP1A2 and may modestly increase ropivacaine clearance, producing somewhat lower steady-state plasma levels than in non-smokers at equivalent doses.

Monoamine oxidase inhibitors (MAOIs) do not interact with local anesthetics directly through enzyme inhibition of local anesthetic metabolism. However, cocaine presents a specific and clinically important interaction with MAOIs: cocaine inhibits presynaptic monoamine reuptake, and MAOIs prevent catecholamine degradation; the combination produces potentially dangerous accumulation of catecholamines at sympathetic synapses, with risk of hypertensive crisis, severe dysrhythmia, and hyperpyrexia. Cocaine should be avoided entirely in patients currently taking or recently discontinuing an monoamine oxidase inhibitor (MAOI).³ Epinephrine-containing local anesthetic solutions in patients on non-selective MAOIs require similar caution, as the vasopressor response to exogenously administered epinephrine may be exaggerated; this interaction is less consistent than the cocaine-MAOI combination but warrants careful consideration in patients on phenelzine or tranylcypromine.